Fully cell-free process aims to democratize personalized cancer therapeutics with shorter turnaround and negligible bioburden ...

MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.

Cervical cancer is one of the most common tumour types in women, with 14,500 new cases diagnosed every year in the US and 4,300 deaths.

Count Mike Etchamendy, 69, of Big Bear Lake, California, as part of that lobby. Since 2013 he’s flown to the East Coast ...